— Why it moved
Why ICCM Stock More Than Doubled Today — June 17, 2026
A 70% install-base update hit a 1.5M-share float with half of it sold short — IceCure went from $4.60 to $9.54 in 47 minutes.
What moved it
IceCure reported 70% growth in the active U.S. install base for ProSense, its breast-cancer cryoablation system that got FDA marketing authorization last October, plus fresh kidney-tumor data at ECIO showing roughly 90% recurrence-free outcomes. Real headlines. Very small company underneath them.
The mechanics
The float is 1.5M shares on a ~$6M cap, and short interest sat near 49% of float. At that size the news barely matters — 151M shares traded, so the float turned over about 100 times. Squeeze fuel plus a story equals vertical.
Numbers
- Cap: ~$6M / float: 1.5M
- Volume: ~151M (float turned ~100x)
- Prev close: $2.13 → gap +99%
- Short interest: ~49% of float
- 52w range: $2.12–$42.00
Where it ended up
Stock Pulse flagged it at 9:34 ET at $4.60. Forty-seven minutes later it printed $9.54, up 107%. An afternoon retest of $9.47 failed, and it closed at $6.39 — still 39% above the alert, but a third off the high.
Reality check
- The fade was real: anyone chasing the morning top was down by the close.
- The same day it announced a $5.5M private placement, dilution nearly the size of its entire market cap. And it's 95% below its 52-week high.
- This already happened. It's a breakdown of why it ran, not a reason to buy it.